Adverse Reactions to Cotrimoxazole in HIV-infected Patients: Predictive Factors and Subsequent HIV Disease Progression
暂无分享,去创建一个
F. Raffi | C. Leport | P. Yeni | Suzanne Izard | C. Rabaud | J. Aboulker | V. Meiffrédy | I. Charreau | S. Izard | F. Guillemin | Catherine Leport | Isabelle Charreau | François Raffi | Vincent Meiffredy | Francis Guillemin | Patrick Yeni | Jean-Pierre Aboulker | F. Guillemin
[1] R. Salamon,et al. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. , 1998, Controlled clinical trials.
[2] C. Leport,et al. Toxoplasmose cérébrale chez les patients infectés par le VIH intolérants au cotrimoxazole. , 1998 .
[3] E. Caumes. Cutaneous adverse reactions and CD4+ cell counts in human immunodeficiency virus-infected patients receiving trimethoprim-sulfamethoxazole. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] Steve Kaye,et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial , 1997, The Lancet.
[5] G. Bratt,et al. N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients. , 1997, The Journal of infection.
[6] G. Guyatt,et al. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[7] I. Keet,et al. Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] R. Salamon,et al. Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] J. Ward,et al. Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends , 1996, AIDS.
[10] J. Darbyshire,et al. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.
[11] M. Moroni,et al. Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial , 1996 .
[12] A. Antinori,et al. Aerosolized pentamidine, cotrimoxazole and dapsone‐pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis , 1995, AIDS.
[13] T. Vree,et al. Pathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic? , 1995, AIDS.
[14] É. Oksenhendler,et al. Toxoplasma gondii infection in advanced HIV infection , 1994, AIDS.
[15] A. S. Gross,et al. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim‐sulphamethoxazole in HIV‐infected patients , 1994, AIDS.
[16] Roujeau Jc. TOXIDERMIES AU COURS DE L'INFECTION A VIH , 1994 .
[17] K. McAdam,et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya , 1993, The Lancet.
[18] C. A. Kennedy,et al. Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: lack of hematologic toxicity and relationship of side effects to CD4+ lymphocyte count. , 1993, The Journal of infectious diseases.
[19] H. Waskin,et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. , 1992, The New England journal of medicine.
[20] A. Cribb,et al. Sulfamethoxazole is metabolized to the hydroxylamine in humans , 1992, Clinical pharmacology and therapeutics.
[21] P. Fultz,et al. Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation. , 1992, AIDS research and human retroviruses.
[22] J. V. D. van der Meer,et al. Cotrimoxazole is effective as primary prophylaxis for toxoplasmic encephalitis in HIV-infected patients: a case control study. , 1997, Scandinavian journal of infectious diseases.
[23] P. Ambroise‐Thomas,et al. [Update on consensual proposals (1993 February). Role of cotrimoxazole in the primary prevention of toxoplasmosis in patients with HIV infection]. , 1993, Annales de medecine interne.
[24] D.,et al. Regression Models and Life-Tables , 2022 .